Overcoming therapeutic resistance that inevitably develops is one of the major challenges in treating lung cancer. Non-small cell lung cancers that harbor mutations in the epidermal growth factor receptor (EGFR) are initially responsive to targeted therapies known as EGFR tyrosine kinase inhibitors (TKIs). However, most patients eventually develop resistance to these therapies. One such targeted [...]
News: stand up to cancer
Stand Up To Cancer (SU2C), the nonprofit organization that helps fund various Vanderbilt-Ingram Cancer Center (VICC) investigators, returns to prime time television for its third broadcast Friday, Sept. 7, at 7 p.m. The hourlong show featuring Hollywood celebrities, recording artists and sports figures will include special performances and a celebrity phone/multi-media bank that will allow [...]
A breast cancer patient who has enrolled in two clinical research trials at Vanderbilt-Ingram Cancer Center was the only presenter to receive a standing ovation during a recent Stand Up To Cancer (SU2C) news briefing at the American Association for Cancer Research (AACR) annual meeting in Chicago. Jeanette Daniel, 51, a metastatic breast cancer patient, [...]
A study led by Vanderbilt-Ingram Cancer Center investigators has identified a gene expression pattern that may explain why chemotherapy prior to surgery isn’t effective against some tumors and suggests new therapy options for patients with specific subtypes of breast cancer. The study by lead author Justin Balko, Pharm.D., Ph.D., was published online June 10, 2012 [...]
Jeffrey Sosman, M.D., professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), has been named to a melanoma research Dream Team of cancer investigators supported by Stand Up To Cancer (SU2C) and the Melanoma Research Alliance (MRA). Sosman is among the Dream Team’s principal investigators who will work closely to write the genomic-driven clinical trials and [...]
Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The findings, reported in two papers in the Proceedings of the National Academy of Sciences (PNAS), suggest that upregulation of the HER3 receptor limits the effectiveness of two classes [...]
Dozens of moms whose children have been touched by cancer will be shaving their heads and appearing on a television special to support childhood cancer research. The “46 Mommas,” including women from the Nashville area, will participate in the shaving event in Los Angeles on Sept. 7, and then will appear onstage during the Stand [...]
At year-end, it is customary to review the accomplishments of the year that is ending and look with anticipation to the year ahead. By any measure, 2009 has been a year of remarkable progress for the Vanderbilt-Ingram Cancer Center.
Breast cancer researchers gathered earlier this month for the annual San Antonio Breast Cancer Symposium. In this video interview with the American Association for Cancer Research, you will hear Vanderbilt-Ingram Cancer Center’s Dr. Carlos Arteaga discuss translational insights for clinical research and practice at the meeting, as well as his exciting research in women’s cancer as part of a Stand Up To Cancer “Dream Team.”
William Pao, M.D., Ph.D., associate professor of Medicine, Vanderbilt-Ingram Cancer Center, has been awarded a grant from Stand Up to Cancer (SU2C) to study molecules that could speed up the search for new cancer drugs and targets. He is one of 13 young cancer investigators to earn a grant from SU2C.